Original articleAlimentary tractDevelopment and Validation of an Inflammatory Bowel Diseases Monitoring Index for Use With Mobile Health Technologies
Section snippets
Design
We performed a prospective, observational study that aimed to develop and validate an mHealth index (mHI) for CD and UC that accurately monitors IBD disease activity using PROs. The study consisted of 2 phases: a development phase and a validation phase. During the development phase the mHIs were developed using collected PROs and clinical disease activity indices. During the validation phase the developed mHIs were validated in an independent cohort.
Development phase
Patients with IBD were identified during
Development Phase
In total, 219 patients (110 CD and 109 UC) were included in the development phase of the study (Figure 1A, Table 2). In 108 out of 110 patients with CD the HBI was calculated, whereas the CDAI could only be calculated in 93 out of 110. The pMayo, SCCAI, and modified Truelove and Witts index were calculated in all patients with UC. Complete laboratory and stool tests were obtained from only 48% of patients. Despite intensive follow-up by a dedicated research nurse (E.K.), 39% of patients did not
Discussion
We developed 2 questionnaires of 4 items consisting solely of PROs for remote monitoring of patients with IBD, which can be used on mobile technology. The questionnaires were validated in a multicenter validation study and showed excellent characteristics to monitor clinical disease activity and symptom changes. As previously shown, UC clinical disease activity highly correlates with endoscopic disease activity, whereas correlation between CD symptoms and endoscopic findings is poor.21
Although
References (22)
- et al.
Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data
Lancet
(2012) - et al.
TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): design and implementation of randomized clinical trial
Contemp Clin Trials
(2015) - et al.
Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease
Clin Gastroenterol Hepatol
(2014) - et al.
Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity
Clin Gastroenterol Hepatol
(2010) - et al.
The emerging field of mobile health
Sci Transl Med
(2015) - The Smartphone Difference. Pew Research Center, April 2015. Available at:...
Is there an app to solve app overload?
JAMA
(2015)- Available at: http://www.medivo.com/gi/. Accessed May 13,...
- Available at: http://www.ibdetermined.org/Tracker.aspx. Accessed: May...
- et al.
National standards for diabetes self-management education and support
Diabetes Care
(2013)
Electronic symptom reporting between patient and provider for improved health care service quality: a systematic review of randomized controlled trials. part 1: state of the art
J Med Internet Res
Cited by (53)
Treatment goals in IBD: A perspective from patients and their partners
2022, PEC InnovationDisease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities
2022, GastroenterologyCitation Excerpt :Use of this app has been shown to result in improved QOL as well as perceived quality of care in patients with IBD.135 Another example is the UCLA eIBD app, which measures a validated 4-question PRO that correlates with disease activity in IBD.141 One of the key issues with mobile-based applications is that they are only effective if users input data.
Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals
2019, Clinical Gastroenterology and HepatologyTreat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?
2019, Gastrointestinal Endoscopy Clinics of North AmericaPrevalence and Appropriateness of Polypharmacy in Older Adults with Inflammatory Bowel Diseases
2024, Digestive Diseases and Sciences
Conflicts of interest The authors disclose no conflicts.
Funding This study was partly supported by a grant from Genova Diagnostics. Genova Diagnostics provided stool collection kits and performed fecal calprotectin testing during the study.